Earnings Call Summary | NeueHealth(NEUE.US) Q2 2024 Earnings Conference
Earnings Call Summary | NeueHealth(NEUE.US) Q2 2024 Earnings Conference
Adjusted EBITDA guidance for the full year 2024 is reaffirmed to be between $15 million and $25 million.The following is a summary of the NeueHealth, Inc. (NEUE) Q2 2024 Earnings Call Transcript:
以下是NeueHealth, Inc.（NEUE）2024年第二季度業績會議要點摘要：
Financial Performance:
金融業績：
NeueHealth reported Q2 2024 consolidated revenue of $226 million with a gross margin of $48.3 million.
The company delivered enterprise adjusted EBITDA of $4 million for the quarter.
Adjusted EBITDA guidance for the full year 2024 is reaffirmed to be between $15 million and $25 million.
Segmented financials include $77 million revenue from NeueCare and $152.1 million from NeueSolutions.
NeueHealth報告2024年第二季度的綜合收入爲2.26億美元，毛利率爲4830萬美元。
該公司本季度企業調整後EBITDA爲400萬美元。
2024年調整後的EBITDA指導範圍仍爲1500萬美元至2500萬美元之間。
分部財務包括NeueCare的7700萬美元營業收入和NeueSolutions的15210萬美元。
Business Progress:
業務進展：
NeueHealth secured a term loan of $150 million to strengthen capital structure.
The company continues to expand its value-driven, consumer-centric care model, aiming to deliver better health outcomes.
Operational focus on engaging consumers with personalized care plans.
Strategic expansion planned in both existing and new geographic regions through robust pipeline.
Efforts include serving diverse consumer populations and partnering with a variety of providers.
NeueHealth獲得了1.5億美元的長期貸款，以加強資本結構。
該公司繼續擴大其以價值驅動、以消費者爲中心的護理模型，旨在提供更好的健康結果。
運營重點在於通過個性化護理計劃吸引消費者。
計劃在現有和新的地理區域進行戰略性擴張，通過強大的管道。
努力包括爲不同消費群體提供服務，並與各種提供商合作。
Opportunities:
機會：
Plans to expand payer and provider partnerships and grow consumer segments across new geographies.
Projected revenue growth from NeueCare and NeueSolutions segments.
計劃擴大支付者和服務提供商的合作伙伴關係，在新的地理區域擴大消費者群體。
預計NeueCare和NeueSolutions部門的收入增長。
Risks:
風險：
Continued wind down of the ACA insurance business could present financial or strategic challenges.
繼續逐步擺脫ACA保險業務可能會帶來財務或戰略方面的挑戰。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
